September 21, 2020

The Niche

Knoepfler lab stem cell blog

Ian Kerridge

4 min read

The ability of for-profit stem cell clinics to pitch unproven, risky stem cell offerings to patients may soon get much tougher in Australia. The country’s Therapeutic Goods Administration (TGA), which has some similar responsibilities there as the FDA does here in the U.S., announced planned new reforms that’ll put stem cell clinics under more scrutiny and more thorough oversight. Hopefully it’ll in many ways provide patients with more protections. While details remain to be determined, there are four major components to the TGA policy change, which …Read More